Eledon Pharmaceuticals and NewcelX Ltd. announced a collaborative research agreement on March 9 2026 to combine NewcelX’s lead stem‑cell‑derived islet program, NCEL‑101, with Eledon’s investigational anti‑CD40L monoclonal antibody, tegoprubart (AT‑1501). The partnership is designed to create a durable, immune‑protected islet replacement that could move toward a functional cure for type 1 diabetes.
The collaboration leverages Eledon’s extensive transplant experience, having treated more than 100 patients with tegoprubart in kidney, heart and other transplant settings. Eledon’s Phase 2 BESTOW trial in kidney transplantation demonstrated a favorable safety profile, and the company is advancing tegoprubart into Phase 3 with a planned launch by the end of 2026. In an investigator‑initiated study of tegoprubart in islet transplantation, early results showed insulin independence in patients, underscoring the potential synergy with NCEL‑101.
NewcelX’s NCEL‑101 is a scalable, off‑the‑shelf stem‑cell‑derived islet therapy aimed at addressing the shortage of functional insulin‑producing cells. The partnership is expected to accelerate development timelines, clarify regulatory pathways, and enhance the clinical value of both programs. By combining tegoprubart’s immune‑modulating capabilities with NCEL‑101’s cell replacement technology, the two companies aim to overcome the autoimmune attack that has limited the durability of previous islet transplant approaches.
Eledon’s focus has historically centered on kidney transplantation, but the new collaboration expands its therapeutic reach into type 1 diabetes. The partnership could open a new revenue stream for Eledon while reinforcing the commercial viability of its CD40L platform. Eledon recently completed a $57.5 million financing round, which is expected to support operations into the second quarter of 2027, and the company reported a strong current ratio of 6.74, indicating solid financial health.
The collaboration places both companies in a competitive landscape that includes Vertex Pharmaceuticals, ViaCyte and Sernova, all developing stem‑cell‑based treatments for type 1 diabetes. The combination of tegoprubart’s immune modulation with NCEL‑101’s islet replacement directly addresses the key challenge of achieving durable insulin independence without chronic immunosuppression.
The partnership underscores Eledon’s strategy to broaden the application of its tegoprubart platform beyond kidney transplantation, while providing NewcelX with a partner that brings extensive transplant experience and a proven track record of navigating complex regulatory pathways.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.